Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Atheroma and calcium antagonists]

P Lechat1, P Hadjiisky

  • 1Service de Pharmacologie, C.H.U. Pitié-Salpétrière, Paris.

Therapie
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Calcium antagonists show promise in preventing atherosclerosis by reducing arterial wall cholesterol. Further human studies are needed to confirm their clinical relevance in managing this cardiovascular disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects.

Fundamental & clinical pharmacology·2004
Same author

[Anticoagulant treatment in atrial fibrillation].

Annales de cardiologie et d'angeiologie·2003
Same author

Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis.

Circulation·2003
Same author

Sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2003
Same author

Pharmacodynamics and pharmacokinetics of single nasal (5 mg and 10 mg) and oral (50 mg) doses of ephedrine in healthy subjects.

European journal of clinical pharmacology·2001
Same author

[Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II].

Therapie·2001
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Area of Science:

  • Cardiovascular Science
  • Pharmacology

Context:

  • Atherosclerosis is a chronic inflammatory disease characterized by lipid deposition in arterial walls.
  • Calcium ions are implicated in the development of atherosclerotic lesions.
  • Calcium antagonists have demonstrated potential anti-atherogenic properties.

Purpose:

  • To explore the anti-atherogenic effects of calcium antagonists.
  • To investigate the potential mechanisms by which calcium antagonists prevent atherosclerosis.
  • To assess the clinical relevance of calcium antagonists in atherosclerosis treatment.

Summary:

  • Calcium antagonists may prevent atherosclerosis by reducing arterial wall cholesterol levels, independent of plasma lipid profiles.
  • The protective mechanism of calcium antagonists appears to be primarily preventive, requiring early administration before lesion onset.

Related Experiment Videos

  • Experimental studies suggest a role for calcium antagonists in managing atherosclerosis, but clinical relevance requires further investigation.

    • Impact:

    • Calcium antagonists represent a potential therapeutic strategy for atherosclerosis and its complications.
    • Early intervention with calcium antagonists could offer a novel approach to cardiovascular disease prevention.
    • Further clinical trials are essential to validate the efficacy and safety of calcium antagonists in human atherosclerosis.